Imaging of tumor hypoxia to predict treatment sensitivity

Current Pharmaceutical Design

Volumn 14, Issue 28, 2008, Pages 2932-2942

  Minn, Heikki ^a   Gronroos T J ^a   Komar, G ^a   Eskola, O ^a   Lehtio K ^a   Tuomela, J ^a   Seppanen M ^a   Solin, O ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

2 nitroimidazoles; Hypoxia; PET; Radionuclide imaging

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITROIMIDAZOL 1 YL) N (3 FLUOROPROPYL)ACETAMIDE F 18; 2 (2 NITROIMIDAZOL 1 YL) N (3,3,3 TRIFLUOROPROPYL)ACETAMIDE F 18; 2 NITROIMIDAZOLE DERIVATIVE; COPPER 62; COPPER 64; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; MISONIDAZOLE; OXYGEN; TECHNETIUM 99M; UNCLASSIFIED DRUG; 2-(2-NITRO-1H-IMIDAZOL-1-YL)-N-(2,2,3,3,3-PENTAFLUOROPROPYL)ACETAMIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETANIDAZOLE; FLUORINATED HYDROCARBON; FLUOROERYTHRONITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE QUALITY; ISOTOPE LABELING; LIPOPHILICITY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NON INVASIVE MEASUREMENT; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIOCHEMISTRY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CELL HYPOXIA; COMPARATIVE STUDY; DRUG RESISTANCE; METHODOLOGY; NEOPLASM; SCINTISCANNING;

ANIMALS; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; ETANIDAZOLE; HUMANS; HYDROCARBONS, FLUORINATED; NEOPLASMS; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 58149389528     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786404380     Document Type: Review

References (74)

1. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 39-47
2. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: Impact on biology, prognosis and treatment of solid malignant tumors. Onkologie 2004; 27: 83-90.
3. Hoogsten IJ, Marres HA, van der Kogel AJ, Kaanders JH. The hypoxic microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol) 2007; 19: 385-96.
4. Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 2006; 3: E47.
7. Chan DA, Giaccia AJ. Hypoxia, gene expression and metastasis. Cancer Metastasis Rev 2007; 26: 333-9.
8. Wilson GD. Hypoxia and prognosis: The oxygen tension mounts. Front Biosci 2007; 12: 3502-18.
9. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998; 46: 229-37.
10. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharmaceut Res 2007; 24: 1172-85.
11. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
12. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10-21.
13. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci 2007; 12: 3483-501.
14. 2 tension measurements. Cancer Res 1991; 51: 3316-22.
15. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
16. Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45-50.
17. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-3
18. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62: 7066-74.
19. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000; 60: 2018-24.
20. Bentzen SM. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 2005; 6: 112-7.
21. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006; 33(Suppl 13): 44-53.
22. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 541-51.
23. Thorwarth D, Soukup M, Alber M. Dose painting with IMPT, helical tomotherapy and IMXT: A dosimetric comparison. Radiother Oncol 2008; 86: 30-4.
24. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007; 17: 861-72.
25. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med 2006; 57: 99-118.
26. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-80.
27. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49: 129S-48.
28. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493-502.
29. Vävere AL, Lewis JS. Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007; 43: 4893-902.
30. 4-methylthiosemicarbazone). J Nucl Med 2008; 49: 201-5.
31. 62Cu Generator. AJR 2008; 190: 427-32.
32. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999; 26: 351-8.
33. 18F-fluoromiso-nidazole. Semin Nucl Med 2007; 37: 451-61.
34. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003; 195: 1-16.
35. 18Ffluoromisonimidazole. Appl Radiat Isot 1993; 44: 1085-91.
36. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 1980; 82: 171-90.
37. 18Ffluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072-9.
38. 18F]FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003; 30: 317-26.
39. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
40. 18F]fluoroetanidazole: A potential new tracer for imaging hypoxia. Nucl Med Biol 1997; 24: 755-60.
41. Lehtiö K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmäki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003; 59: 971-82.
42. 18F]EF1. J Appl Radiat Isot 1999; 51: 643-50.
43. 18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001; 9: 665-75
44. 18F]EF5, a marker for PET detection of hypoxia: Synthesis of precursor and new fluorination procedure. Appl Radiat Isot 2001; 54: 73-80.
45. 18F]EF3 in patients with head and neck tumours: A phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008; 35: 1282-9.
46. Casella V, Ido T, Wolf AP, Fowler JS, MacGregor RR, Ruth TJ. Anhydrous F-18 labeled elemental fluorine for radiopharmaceutical preparation. J Nucl Med 1980; 21: 750-7.
47. 2. Int J Appl Radiat Isot 1985; 35: 117-22.
48. 2. Nucl Med Biol 1996; 23: 189-99.
49. Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997; 24: 677-83.
50. 18F]EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med (in press).
51. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as probe for hypoxic cells. Radiat Res 1987; 111: 292-304.
52. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990; 122: 301-8.
53. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 513-20.
54. Koch CJ, Hahn SM, Rockwell K, Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: Implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol 2001; 48: 177-87.
55. 18F-EF5. Eur J Nucl Med Mol Imaging 2003; 30: 259-66.
56. 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Label Compd Radiopharm 1999; 42: 3-16.
57. Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 1996; 277: 1049-57.
58. Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9: S4-9.
59. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al. Hypoxia is important in the biology and aggression human glial brain tumors. Clin Cancer Res 2004; 10: 8177-84.
60. Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, et al. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys 2007; 69: 1024-31.
61. 18F]Fluoroerythronitroimidazole: A potential hypoxia marker for PET. J Nucl Med 2001; 42: 1397-404.
62. 18F]EF5 in patients with head and neck cancer. 17th International Symposium on Radiopharmaceutical Chemistry, Aachen, Germany, 30 April -4 May, 2007.
63. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-28
64. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-60.
65. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006; 24: 2098-104.
66. 18F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging 2007; 34: 1566-75.
67. 18F]Fluoroerythronitroimidazole PET. J Nucl Med 2001; 42: 1643-52.
68. Graham MM, Peterson LM, Link JM, Evans ML, Rasey JS, Koh WJ, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997; 38: 1631-6.
69. Tolvanen T, Lehtiö K, Kulmala J, Oikonen V, Eskola O, Bergman J, et al. Fluorine-18-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 2002; 43: 1674-80.
70. 18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med 2003; 30: 259-66.
71. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2007; 68: 515-21.
72. Bauer M, Wagner CC, Langer O. Microdosing studies in humans: The role of positron emission tomography. Drugs RD 2008; 9(2): 73-81.
73. Cecchi A, Supuran CT. Fluorescence- and spin-labeled carbonic anhydrase inhibitors. Curr Pharm Des 2008; 14(7): 699-707.
74. Duzova A, Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: Current concepts in treatment. Curr Pharm Des 2008; 14(13): 1295-301.